NCT06261021

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Apr 19, 2024
Primary completion: Feb 28, 2025
Completion date: Feb 28, 2025
First posted: Feb 15, 2024
Last posted: Sep 19, 2024
Enrollment: 20
Arms / groups: 2 / —
Source: AACT · ctgov ingestion

Drugs studied

ruxolitinib

Indications studied

Lupus Erythematosus, Discoid

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.

NCT06261021

Timeline

Sponsors

Drugs studied

Indications studied